SA
Go ProLog In
MLYS
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
8 analysts·Limited coverage
72
Score
7 Buy (88%)1 Hold (13%)0 Sell (-1%)
Rating Breakdown
Strong Buy
00%
Buy
788%
Hold
113%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$30.00
+9.6%
Consensus
$52.00
+89.9%
Bull
$56.00
+104.5%
12-Month Target Range8 analysts
$30.00$52.00$56.00
Current $27.38Consensus
Current Price
$27.38
Upside to Consensus
$24.62

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+21686.89%
EPS—
FY2028
Rev+109.82%
EPS—
FY2029
Rev+167.77%
EPS—

Earnings Surprises

Recent Analyst Actions

Mar 13, 2026Jefferies
Mineralys Therapeutics, Inc. (MLYS) PT Lowered to $30 at Jefferies
Target:$30.00
+14.4%from $26.23
Mar 10, 2026H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
Target:$56.00
+105.7%from $27.23
Dec 19, 2025Stifel Nicolaus
Mineralys Therapeutics price target raised to $52 from $45 at Stifel
Target:$52.00
+40.5%from $37.00
Oct 30, 2025H.C. Wainwright
Mineralys Therapeutics price target raised to $52 from $42 at H.C. Wainwright
Target:$52.00
+29.5%from $40.14
May 14, 2025Guggenheim
Mineralys Therapeutics price target lowered to $48 from $52 at Guggenheim
Target:$48.00
+217.7%from $15.11
Apr 2, 2025H.C. Wainwright
Mineralys Therapeutics price target raised to $42 from $30 at H.C. Wainwright
Target:$42.00
+200.0%from $14.00
Apr 2, 2024Goldman Sachs
Goldman Sachs Starts Mineralys Therapeutics, Inc. (MLYS) at Buy, 'Upcoming Pivotal Results Could Surprise on the Upside'
Target:$30.00
+130.2%from $13.03

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance